EUVIMEDEUVIMED entdecken
Fallbericht

Successful Shrinkage of a Giant Cutaneous Squamous Cell Carcinoma with Immunotherapy in a Kidney Transplant Recipient

Theodoros Eleftheriadis, Ioannis Samaras, Antonios Spanos, Athanasios Kotsakis, Ioannis Stefanidis

Experimental and Clinical Transplantation · 2023

DOI: 10.6002/ect.2023.0018 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Experimental and Clinical Transplantation, 2023. Verfasst von Theodoros Eleftheriadis und 4 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Nephrology, Faculty of Medicine, University of Thessaly, Larissa, Greece. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Kidney Transplantation, Skin Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A 56-year-old male living donor kidney transplant recipient presented with a giant cutaneous squamous cell carcinoma in his right parotid region. Programmed radiotherapy had been previously terminated due to lesion ulceration and bleeding. He was characterized as a terminal case. We applied cemiplimab, which is an immune checkpoint inhibitor against the pro-grammed cell death receptor PD-1. After 6 months, the cutaneous squamous cell carcinoma had shrunk and had stopped bleeding. The patient was treated with methylprednisolone, cyclosporine, and mycophenolate mofetil during this period. He had 2 rejection episodes defined as doubling baseline serum creatinine with no other explanation. Both episodes were successfully treated with intravenous methylprednisolone, while immunotherapy was postponed for 10 days. In both cases, serum creatinine returned to baseline within 1 week. Immune checkpoint inhibitors are indicated for invasive cutaneous squamous cell carcinoma therapy, and the risk of acute rejection should not prevent the use of these agents in kidney transplant recipients, because immune checkpoint inhibitors may enhance the quantity and quality of life of such patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Squamous CellKidney TransplantationSkin NeoplasmsMaleHumansMiddle AgedImmune Checkpoint InhibitorsCreatinineQuality of LifeMethylprednisoloneImmunotherapyGraft Rejection

Substanzen

Immune Checkpoint InhibitorsCreatinineMethylprednisolone

Autor:innen und Institutionen

  • From the Department of Nephrology, Faculty of Medicine, University of Thessaly, Larissa, Greece.

Zitieren

APA

Eleftheriadis, T., Samaras, I., Spanos, A., Kotsakis, A., & Stefanidis, I. (2023). Successful Shrinkage of a Giant Cutaneous Squamous Cell Carcinoma with Immunotherapy in a Kidney Transplant Recipient. Experimental and Clinical Transplantation. https://doi.org/10.6002/ect.2023.0018

Vancouver

Eleftheriadis T, Samaras I, Spanos A, Kotsakis A, Stefanidis I. Successful Shrinkage of a Giant Cutaneous Squamous Cell Carcinoma with Immunotherapy in a Kidney Transplant Recipient. Experimental and Clinical Transplantation. 2023. doi:10.6002/ect.2023.0018

BibTeX
@article{Eleftheriadis2023,
  author = {Eleftheriadis, Theodoros and Samaras, Ioannis and Spanos, Antonios and Kotsakis, Athanasios and Stefanidis, Ioannis},
  title = {Successful Shrinkage of a Giant Cutaneous Squamous Cell Carcinoma with Immunotherapy in a Kidney Transplant Recipient},
  journal = {Experimental and Clinical Transplantation},
  year = {2023},
  doi = {10.6002/ect.2023.0018}
}
Kostenlos starten →